期刊文献+

FDA网站药品安全信息发布对我国启示 被引量:2

The enlightenment of FDA drug safety information release for our country
原文传递
导出
摘要 完善我国CFDA网站药品安全信息发布,对指导临床安全用药、避免药品不良反应(ADR)重复发生起重要作用。通过分析我国CFDA网站药品安全信息发布存在的问题,并分析美国FDA网站药品安全信息发布的特点,提出完善建议。我国应借鉴美国经验并结合我国国情,构建药品安全信息专页并从安全信息发布内容、渠道、沟通、宣传4个方面完善我国CFDA网站药品安全信息发布体系。 Improving the security of drug information release in China CFDA website, to guide the clinical medication safety and to avoid repetitive ADR occurred, plays an important role in the safety of drug administration. By analyzing the problems existing in the security of drug information release in China CFDA website, and analyzing the characteristics of American FDA website drug safety information, a sound proposal was put forward. China should learn from the experience of USA combined with Chings national conditions, to establish drug safety information page and to improve the drug safety information release system in China CFDA website from the following four aspects., safety information publication, security information channels, communication and publicity.
作者 樊迪
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第13期1134-1138,共5页 Chinese Journal of Hospital Pharmacy
关键词 FDA网站 CFDA网站 药品安全信息专页 药品安全信息 FDA websitel CFDA website drug safety information page drug safety information
  • 相关文献

参考文献11

二级参考文献10

共引文献12

同被引文献29

  • 1龚时薇,张亮,黄杰敏,詹学锋,姜卫,王成江.药品安全与风险管理[J].中国药房,2007,18(22):1687-1690. 被引量:45
  • 2Motl S, Timpe E, Eichner S. Proposal to improve Med-Watch:decentralized, regional surveillance of adverse drug reactions[J]. Am J Health Syst Pharm, 2004, 61(17):1840. 被引量:1
  • 3FDA. Managing the Risks from Medical Product Use: Report to the FDA Commissioner from the Task Force on Risk Management[EB/OL]. (1999-05)[2015-06-16]. http://www.fda.gov / Safety / Safety of Specific Products /ucm180325.htm. 被引量:1
  • 4FDA. The Future of Drug Safety—Promoting and Protecting the of the Public[EB/OL].(2007-01)[2015-06-16]. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm171627.pdf. 被引量:1
  • 5FDA. Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry[EB/OL].(2015-04)[2015-06-18].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm441226.pdf. 被引量:1
  • 6FDA.Guidance Drug Safety Information-FDA’s Communication to the Public[EB/OL](2007-03) [2015-06-18]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072281.pdf. 被引量:1
  • 7FDA. FDA’s Strategic Plan for Risk Communication[EB/OL].(2015-07-02) [2015-06-18]. http://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm183673.htm. 被引量:1
  • 8FDA. Milestones in U.S. Food and Drug Law History[EB/OL].(2015-09-21) [2015-10-11]. http://www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/ucm128305.htm. 被引量:1
  • 9FDA. FDA’s Risk Communication Research Agenda[EB/OL].(2014-09-03)[2015-06-18]. http://www.fda.gov/scienceresearch/specialtopics/riskcommunication/ucm227141.htm. 被引量:1
  • 10FDA. Guidance Drug Safety Information- FDA’s Communication to the Public[EB/OL]. (2007-03)[2015-06-16]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072281.pdf. 被引量:1

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部